Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Anthracycline-free regimen OK in HER2-negative early breast cancer

Publish date:: March 4, 2019

Key clinical point: Intermediate-to-high risk HER2-negative early breast cancer can be treated with an anthracycline-free regimen.

Major finding: Five-year DFS rates were 89.6% with TC vs. 89.9% with EC-T.

Study details: Randomized clinical trial of 2,449 women with early HER2-negative early breast cancer.

Disclosures: Genomic Health, Sanofi, and Amgen supported the study. Dr. Nitz and multiple coauthors disclosed financial relationships with these companies and others.

Citation:

Nitz U et al. J Clin Oncol. 2019 Feb 20. doi: 10.1200/JCO.18.00028.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Pregnancy after breast cancer is rockier but doesn't increase recurrence risk,

Breast surgery may be a gateway to addictive medication use,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,